SCHEMBL7916902

SCHEMBL7916902

COc1cnc(C(F)(F)F)cc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.40
AXL P30530 1/20 0.38
PTGS2 P35354 2/20 0.36
PTGS1 P23219 1/20 0.36
HCRTR1 O43613 1/20 0.36
KDM4E B2RXH2 3/20 0.35
P2RX3 P56373 2/20 0.35
P2RX2 Q9UBL9 2/20 0.35
HPGD P15428 2/20 0.35
MITF O75030 1/20 0.35
LMNA P02545 1/20 0.35
STAT3 P40763 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CHEK1 O14757 1/20 0.34
L3MBTL1 Q9Y468 4/20 0.34
TRPV4 Q9HBA0 1/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 3/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31045864 0.85 PDE10A (0.43) PDE10AAXLPTGS2PTGS1HCRTR1
SCHEMBL29723713 0.83 PDE10A (0.36) PDE10AAXLPTGS2HCRTR1P2RX3
SCHEMBL24529262 0.83 PDE10A (0.36) PDE10AAXLPTGS2HCRTR1P2RX3
SCHEMBL22161741 0.79 PDE10A (0.40) PDE10APTGS2PTGS1HCRTR1KDM4E
SCHEMBL19899535 0.78 CA2 (0.41) PDE10AKDM4ENPSR1CHEK1L3MBTL1
SCHEMBL30018060 0.78 PDE10A (0.40) PDE10AKDM4EP2RX3P2RX2HPGD
SCHEMBL929688 0.78 PDE10A (0.40) PDE10AKDM4EP2RX3P2RX2HPGD
SCHEMBL20855529 0.76 PDE10A (0.42) PDE10AHCRTR1KDM4EHPGDMITF
SCHEMBL26608181 0.76 L3MBTL1 (0.36) PDE10APTGS2PTGS1L3MBTL1
SCHEMBL17009018 0.76 LCK (0.45) PDE10AHCRTR1KDM4EP2RX3P2RX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373814-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES Novartis AG (CH) 2024-05-29 EP disclosed
CN-117651699-A Compounds and compositions for the treatment of coronavirus related diseases 诺华股份有限公司 2024-03-05 CN disclosed
WO-2023002409-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES NOVARTIS AG (CH) 2023-01-26 WO disclosed
US-6225320-B1 TREATMENT OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTTHERPETIC NEURALGIA MERCK SHARP & DOHME LTD. (GB) 2001-05-01 US disclosed
EP-0989987-A1 SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2000-04-05 EP disclosed
WO-1998054187-A1 SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 1998-12-03 WO disclosed